BioCryst Pharmaceuticals Inc BCRX:NASDAQ

Last Price$11.44NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$11.44 (51)
Ask (Size)$11.45 (2)
Day Low / HighN/A - N/A
Volume2.3 M
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

BioCryst Pharmaceuticals Inc ( NASDAQ )

Price: $11.44
Change: -0.43 (3.62%)
Volume: 2.3 M
4:00PM ET 12/03/2021
 
 

Xencor Inc ( NASDAQ )

Price: $35.16
Change: -1.57 (4.27%)
Volume: 286.8 K
4:00PM ET 12/03/2021
 
 

Nektar Therapeutics ( NASDAQ )

Price: $10.83
Change: -0.58 (5.08%)
Volume: 1.6 M
4:00PM ET 12/03/2021
 
 

Myriad Genetics Inc ( NASDAQ )

Price: $24.38
Change: -1.15 (4.50%)
Volume: 538.7 K
4:00PM ET 12/03/2021
 
 

Editas Medicine Inc ( NASDAQ )

Price: $27.72
Change: -2.31 (7.69%)
Volume: 2.4 M
4:00PM ET 12/03/2021
 

Read more news Recent News

BioCryst Pharmaceuticals Enrolls First Patient in Paroxysmal Nocturnal Hemoglobinuria Trial
10:29AM ET 11/29/2021 MT Newswires

BioCryst Pharmaceuticals (BCRX) said Monday it enrolled the first patient in a pivotal trial of its BCX9930 oral Factor D inhibitor for paroxysmal...

Sector Update: Health Care Stocks Finishing Mixed This Afternoon
4:05PM ET 11/22/2021 MT Newswires

Health care stocks were mixed late Monday afternoon, with the NYSE Health Care Index rising 0.2% while the Health Care Select Sector SPDR ETF (XLV) slipped...

Sector Update: Health Care
3:42PM ET 11/22/2021 MT Newswires

Health care stocks were mixed Monday afternoon, with the NYSE Health Care Index rising 0.2% while the Health Care Select Sector SPDR ETF (XLV) slipped...

Royalty Pharma Acquires Additional Royalty Interests in 2 Drug Candidates Developed by BioCryst
9:15AM ET 11/22/2021 MT Newswires

Royalty Pharma (RPRX), BioCryst Pharmaceuticals (BCRX), and OMERS Capital Markets said Monday Royalty Pharma has acquired additional royalty interests in...

Company Profile

Business DescriptionBioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC. View company web site for more details
Address4505 Emperor Boulevard
Durham, North Carolina 27703-8457
Phone+1.919.859.1302
Number of Employees100
Recent SEC Filing12/02/20214
President, Chief Executive Officer & DirectorJon P. Stonehouse
Executive Director-FinanceMichael L. Jones
Chief Financial Officer, Treasurer & Senior VPAnthony Doyle
Chief Medical Officer & Senior Vice PresidentWilliam P. Sheridan

Company Highlights

Price Open$11.85
Previous Close$11.87
52 Week Range$5.75 - 18.48
Market Capitalization$2.0 B
Shares Outstanding178.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.28
Beta vs. S&P 500N/A
Revenue$20.7 M
Net Profit Margin-198.88%
Return on Equity261.14%

Analyst Ratings as of 11/03/2021

Buy
9
Overweight
0
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset